The White House announced on October 10 that it has reached an agreement with AstraZeneca to lower drug prices. This deal aims to align drug costs with the lowest prices paid by other developed nations, known as the most-favored-nation price. Similar to a previous agreement with Pfizer, AstraZeneca will provide every state Medicaid program access to these reduced prices and offer significant discounts when selling directly to Americans.
AstraZeneca said in a news release that it will benefit from a three-year exemption from tariffs on its products and plans to sell its products on the TrumpRX platform. Additionally, the company has committed to investing $50 billion in U.S. manufacturing and research and development by 2030.
Information from this article can be found here.
